Biote corp.

Description. Filing Group. View. Nov 14, 2023. 424B3. Form of prospectus reflecting facts events constituting substantive change from last form. Registration Statements. View HTML. 0000950170-23-063215.pdf.Biote Corp. (BTMD) Reports Q3 Loss, Lags Revenue Estimates. biote Corp. (BTMD) delivered earnings and revenue surprises of -237.50% and 4.90%, respectively, for the …Corporate Profile Biote operates a high growth, differentiated medical practice-building business within the hormone optimization space. Similar to a franchise model, Biote provides the necessary components to enable practitioners to establish, build, and successfully operate a hormone optimization center to treat patients appropriate for therapy.Item 2.02. Results of Operations and Financial Condition. On November 7, 2023, biote Corp., a Delaware corporation (the “Company”) issued a press release to report the Company’s financial results for the quarter ended September 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build, and implement a program designed to optimize hormone levels. The Company's Biote Method is a comprehensive, end-to-end practice …

When you look at biote Corp’s price-to-sales ratio at 0.83 compared to the industry median at 4.54, this company has a lower price relative to revenue compared to its peers. This could make biote Corp’s stock more attractive for value investors. Now, let’s assess biote Corp’s EV/EBITDA ratio, also known as enterprise multiple.

Inside Biote Corp.'s 10-K Annual Report: Revenue - Product Highlight. Our ability to raise additional capital through the sale of equity or convertible debt securities could be significantly impacted by the resale of shares of Class A common stock by selling securityholders pursuant to the registration statement on Form S-1 filed with the SEC on …In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Stock, par value $0.0001 per share, of biote Corp., a Delaware corporation.As of December 01, 2023, biote Corp had a $363.1 million market capitalization, putting it in the 52nd percentile of companies in the Professional Information Services industry. biote Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. biote Corp’s trailing 12-month revenue is $184.1 million with a ...Biote Corp. Consolidated Statements of Operations (In Thousands, except per share values) (Unaudited) Three Months Ended March 31, 2023. 2022. Revenue: Product revenue $ 44,155 $ 36,758. Service ...

Nov 7, 2023 · Third Quarter 2023 Financial Highlights. (All financial result comparisons made are against the prior year period) Revenue of $45.6 million, an 8.5% increase. Gross profit margin of 68.9%, a 70-basis point increase. Net income of $19.6 million, representing net income margin of 43.1%, and basic earnings per share of $0.25, compared to net ...

Corporate Profile. Biote operates a high growth, differentiated medical practice-building business within the hormone optimization space. Similar to a franchise model, Biote provides the necessary components to enable practitioners to establish, build, and successfully operate a hormone optimization center to treat patients appropriate for therapy.

IRVING, Texas--(BUSINESS WIRE)--Jun. 5, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the pricing of an underwritten offering of 5,217,392 shares of its Class A common stock by one its stockholders at a price of $5.35 per share.On May 26, 2022 (the “Closing Date”), the Business Combination with Holdings was consummated, resulting in Biote being organized in an “Up-C” structure, and HYAC as the registrant changed its name to “biote Corp. ” Biote’s headquarters are located at 1875 W. Walnut Hill Ln #100 Irving, Texas 75038.biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient’s hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements.PDF Version. IRVING, Texas -- (BUSINESS WIRE)--Oct. 10, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical …Jun 10, 2022 · Innovative physician leader brings over 20 years of experience to Biote’s executive team. IRVING, Texas--(BUSINESS WIRE)--Jun. 16, 2022-- biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, today announced that it has appointed Ross W. McQuivey, M.D., as its Chief Medical Officer, effective ... Oct 24, 2023 ... 24, 2023-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will ...About BTMD. biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements.

Biote Schedules Third Quarter 2023 Financial Results Release and Conference Call. -- (BUSINESS WIRE)--Oct. 24, 2023-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide third quarter financial results on , after the close of the market. A conference ...About Biote. Founded in 2012, Biote has experience phenomenal growth over the last decade. The Biote state-of-the-art training facility hosts physicians, healthcare providers, and medical staff members monthly during the Biote Method learning and certification process. To date, more than 6,400 medical practitioners have successfully completed ... Our success will depend upon whether the Biote Method and our Biote-branded dietary supplements attain significant market acceptance among clinics, practitioners and their patients; Outsourcing facilities that produce bioidentical hormone pellets that we offer training on in the Biote Method and failure by those parties to adequately perform their …Biote Corp. Consolidated Statements of Operations (In Thousands, except per share values) (Unaudited) Three Months Ended March 31, 2023. 2022. Revenue: Product revenue $ 44,155 $ 36,758. Service ...Nov 30, 2023 · biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and ... Biote Corp. (BTMD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.08. This compares to loss of $0.09 per share a year ago. These figures are adjusted ...

Biote Holdings is merging with blank-cheque firm Haymaker Acquisition in a $737m (£556.8m) transaction to take it public, the companies have announced. Haymaker Acquisition stock rose 0.70% to $10.70 from $10 per share after the market open but fell to $9.91 per share by noon EDT (UTC-5). Haymaker Acquisition trades over the Nasdaq exchange ...biote Corp Stock Price History. biote Corp’s price is currently up 9.01% so far this month. During the month of November, biote Corp’s stock price has reached a high of $5.81 and a low of $5.28. Over the last year, biote Corp has hit prices as high as $8.22 and as low as $2.75. Year to date, biote Corp’s stock is down 40.71%.

biote Corp. (Name of Issuer) Common Stock, $0.0001 par value . Common Stock, Par Value $0.001 per share (Title of Class of Securities) 090683103 (CUSIP Number) Michael Braner. 325 Capital LLC. 757 Third Avenue, 20 th Floor. New York, NY 10017. 646-774-2904 (Name, Address and Telephone Number of Person.A certain stockholder of biote Corp., a Delaware corporation (the “Company”) named in Schedule II attached hereto (the “Selling Stockholder”), propose, subject to the terms and conditions herein, to sell 5,217,392 shares (the “Firm Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”).Jun 8, 2023 · As previously disclosed, on May 9, 2023, biote Corp. (the “ Company ”), commenced (i) its offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per share (“ Common Stock ”), of the Company, at an exercise price of $11.50 per share (the “ Warrants ”), the opportunity to receive 0.23 shares of Common ... Nov 7, 2023 · Biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build, and implement a program designed to optimize hormone levels. Biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build, and implement a program desig ned to optimize hormone levels. The Company's Biote Method is a comprehensive, end-to-end practice …The United States Marines traces its roots back to 1776, and it’s the oldest military institution in the country. When Marines earn distinction during their service, the Marine Corps recognizes this service with a variety of medals and ribb...

Biote Holdings is merging with blank-cheque firm Haymaker Acquisition in a $737m (£556.8m) transaction to take it public, the companies have announced. Haymaker Acquisition stock rose 0.70% to $10.70 from $10 per share after the market open but fell to $9.91 per share by noon EDT (UTC-5). Haymaker Acquisition trades over the Nasdaq exchange ...

Dec 1, 2023 · Stock analysis for Biote Corp (BTMD:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Terry joined Biote to drive permanent industry innovation in the hormone optimization market, addressing the 200 million individuals in the U.S. who suffer from hormone imbalance. Terry’s team-first focus has consistently resulted in growth, both in the financials of the $100 million to $2.5 billion companies she has led, and in the personal ... In this case, outsourcing facilities, Carie Boyd’s Prescription Shop and AnazaoHealth Corporation, produced the pellets, but they were marketed by BioTe Medical, which was not registered with ...Biote Appoints Samar Kamdar as Chief Financial Officer IRVING, TX, August 24, 2022 — biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as its Chief Financial Officer. On November 3, 2022, the Board of Directors of biote Corp. increased the size of the Board from six to seven directors and, following the recommendation of the Nominating and Corporate Governance Committee, appointed Debra L. Morris to serve as a member of the Board and as a member of the Board's Audit Committee, effective …Description of Business—biote Corp. (inclusive of its consolidated subsidiaries, the “Company” or “Biote”) is a Delaware incorporated company headquartered in Irving, Texas. The Company was founded in 2012 and trains physicians and nurse practitioners in hormone optimization using bio-identical hormone replacement pellet …IRVING, Texas--(BUSINESS WIRE)--Jul. 20, 2022-- biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, will report its financial results for the second quarter ended June 30, 2022, after market close on Tuesday, August 9, 2022. Terry Weber, Chief …Feb 9, 2023 · IRVING, Texas--(BUSINESS WIRE)--Feb. 9, 2023-- Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 28, 2023, after the close of the market. Biote Corp. (BTMD) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.27 per share a year ago.biote Corp. , which belongs to the Zacks Medical - Products industry, posted revenues of $49.26 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 5.33%.Biote Corp. Warrant Tender Offer. Financial Advisor June 2023. $49,680,000. GEN Restaurant Inc. IPO. Sole Book-Running Manager June 2023 View Details.Terry joined Biote to drive permanent industry innovation in the hormone optimization market, addressing the 200 million individuals in the U.S. who suffer from hormone imbalance. Terry’s team-first focus has consistently resulted in growth, both in the financials of the $100 million to $2.5 billion companies she has led, and in the personal ...

Biote to be Listed on Nasdaq through a Business Combination with Haymaker Acquisition Corp. III Biote is a high-growth medical practice-building company operating within the multi-billion dollar ...Nov 14, 2023 · Description. Filing Group. View. Nov 14, 2023. 424B3. Form of prospectus reflecting facts events constituting substantive change from last form. Registration Statements. View HTML. 0000950170-23-063215.pdf. The adverse event information our investigators found suggested compounded hormone pellets were possibly associated with endometrial cancer, prostate cancer, strokes, heart attacks, deep vein ...Instagram:https://instagram. stock options brokerbrokers with lowest feessimulated futures tradingva dental insurance delta dental biote Corp. Up to 72,069,990 Shares of Class A Common Stock . Up to 67,856,462 Shares of Class A Common Stock . Up to 5,566,666 Warrants . This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-265714), as amended.Dec 31, 2022 · Biote Corp. Consolidated Statements of Cash Flows (In Thousands) (Unaudited) Year Ended December 31, 2022 2021 Operating Activities: Net income $ 1,324 $ 32,619 Adjustments to reconcile net income to net cash (used in) provided by operating activities: Depreciation and amortization 2,199 1,400 Bad debt expense (recoveries) nasdaq amzn dividendbest ai related stocks biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimizatio best broker futures trading Management reiterates its 2022 guidance of $160-166 million in revenue and $46-50 million in adjusted EBITDA. 1. IRVING, TX, May 11, 2022 – Biote, a high growth, differentiated medical practice-building business within the hormone optimization space, today announced financial results for the first quarter of 2022.Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 May. 09: CI Certain Restricted Stock Units of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023. Apr. 05: CI Certain Stock Options of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023.Biote derives revenues by contractually sharing in the profit generated by Biote-certified practitioners and through the sale of its Biote-branded nutraceutical products. Biote-certified practitioners deliver personalized hormone replacement therapy to relieve the symptoms of hormonal imbalance, which affects approximately 200 million Americans.